A Look At InnoCare Pharma (SEHK:9969) Valuation After Recent Share Price Weakness

Simply Wall St.06-03

AdvertisementRecent performance and context InnoCare Pharma (SEHK:9969) has drawn attention after its share price closed at HK$11.26, with the stock down 2.3% over the past day and 3.7% over the past ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2640977761?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-06-03 14:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2640977761","market":"hk","top_or_hot":-1,"title":"A Look At InnoCare Pharma (SEHK:9969) Valuation After Recent Share Price Weakness","media":"Simply Wall St.","content":"<div>\n<p>AdvertisementRecent performance and context InnoCare Pharma (SEHK:9969) has drawn attention after its share price closed at HK$11.26, with the stock down 2.3% over the past day and 3.7% over the past ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9969/innocare-pharma-shares/news/a-look-at-innocare-pharma-sehk9969-valuation-after-recent-sh-3\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>A Look At InnoCare Pharma (SEHK:9969) Valuation After Recent Share Price Weakness</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nA Look At InnoCare Pharma (SEHK:9969) Valuation After Recent Share Price Weakness\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-06-03 14:16 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9969/innocare-pharma-shares/news/a-look-at-innocare-pharma-sehk9969-valuation-after-recent-sh-3><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AdvertisementRecent performance and context InnoCare Pharma (SEHK:9969) has drawn attention after its share price closed at HK$11.26, with the stock down 2.3% over the past day and 3.7% over the past ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9969/innocare-pharma-shares/news/a-look-at-innocare-pharma-sehk9969-valuation-after-recent-sh-3\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09969","symbol_name":"诺诚健华","start_time":0,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9969/innocare-pharma-shares/news/a-look-at-innocare-pharma-sehk9969-valuation-after-recent-sh-3","article_id":"2640977761","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9969/innocare-pharma-shares/news/a-look-at-innocare-pharma-sehk9969-valuation-after-recent-sh-3","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2640977761","pubTimestamp":1780467404,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Recent performance and context\nInnoCare Pharma (SEHK:9969) has drawn attention after its share price closed at HK$11.26, with the stock down 2.3% over the past day and 3.7% over the past week.\nThat shorter term weakness sits alongside a decline of 18.6% over the past month and a year to date fall of 9.9%. Over a longer period, the stock is up 2.9% over the past 3 months and 2.0% over the past year.\nSee our latest analysis for InnoCare Pharma.\nRecent trading has been choppy, with the share...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"09969":"诺诚健华","BK1574":"生物医药B类股","BK1161":"生物科技"},"translate_title":"近期股价疲软后诺诚健华医药（SEHK：9969）估值一览","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09969":0.9},"content_text":"AdvertisementRecent performance and context InnoCare Pharma (SEHK:9969) has drawn attention after its share price closed at HK$11.26, with the stock down 2.3% over the past day and 3.7% over the past week. That shorter term weakness sits alongside a decline of 18.6% over the past month and a year to date fall of 9.9%. Over a longer period, the stock is up 2.9% over the past 3 months and 2.0% over the past year. See our latest analysis for InnoCare Pharma. Recent trading has been choppy, with the share price retreating in the short term but still showing a modest gain over the past year. The 3 year total shareholder return of 58.6% highlights how earlier investors have been rewarded despite a weaker 5 year total shareholder return. If you are comparing InnoCare Pharma with other healthcare and biotech opportunities, this could be a good moment to scan the broader sector using our screener for 130 healthcare AI stocks With the share price easing in recent weeks but trading at a sizeable discount to analyst targets and intrinsic estimates, investors may ask whether InnoCare Pharma is undervalued at this level or whether the market is already pricing in future growth. Most Popular Narrative: 43.2% Undervalued At HK$11.26, the most followed narrative for InnoCare Pharma points to a fair value of HK$19.82, framing the recent pullback against a materially higher intrinsic estimate.  The analysts have a consensus price target of HK$19.82 for InnoCare Pharma based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of HK$22.21, and the most bearish reporting a price target of just HK$17.43.  Read the complete narrative. Want to understand why a company with shrinking forecast earnings could still command a premium valuation in this narrative? The answer lies in how revenue growth, margin reset and rich future multiples are stitched together into a single story of long term value. Result: Fair Value of HK$19.82 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, this hinges on heavy R&D spending and reliance on a few key drugs, so any clinical or commercialization setbacks could quickly weaken that upside story. Find out about the key risks to this InnoCare Pharma narrative. Another way to look at value The narrative points to a fair value of HK$19.82, but the current P/E of 22.6x sits well above the fair ratio of 7.9x, even though it is below both peer (32.8x) and Asian biotech (31.9x) averages. That creates a mixed picture of relative value and re rating risk. See what the numbers say about this price — find out in our valuation breakdown. SEHK:9969 P/E Ratio as at Jun 2026Next Steps Given the mix of caution and optimism in this article, it may be useful to move quickly, review the data yourself and decide where you stand using our breakdown of 4 key rewards and 2 important warning signs Looking for more investment ideas? If you stop at one stock, you risk missing out on other opportunities that fit your style, so broaden your watchlist with focused screeners that do the heavy lifting for you.  Target potential mispriced opportunities by scanning 211 high quality undervalued stocks that combine quality fundamentals with more modest valuations. Prioritise resilience by checking out 283 resilient stocks with low risk scores designed to highlight companies with steadier risk profiles. Hunt for future standouts with screener containing 509 high quality undiscovered gems before they appear on everyone else's radar.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2640977761","isCrawlerRequest":true}